Trump’s Budget Proposal Swings At Drug Prices With A Glancing Blow
The Trump administration rolled out a list of actions to attack drug prices, but most dance around the edges.
Drugs
1,041-1,060 of 1,313 results
-
-
KHN On NPR: The Uniquely American Problem Of High Prescription Drug Costs
Kaiser Health News Editor-in-Chief Elisabeth Rosenthal discusses drug costs with Scott Simon, the host of NPR's Weekend Edition. Listen to the broadcast and read a transcript of that conversation.
-
Podcast: KHN鈥檚 鈥榃hat The Health?鈥 There鈥檚 A Really Big Health Bill In That Budget Deal
In this episode of KHN鈥檚 鈥淲hat the Health?鈥 Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo, Joanne Kenen of Politico and Margot Sanger-Katz of The New York Times discuss the health policy changes included in the just-concluded bipartisan budget deal on Capitol Hill. The panelists also talk about the final enrollment numbers for individual insurance purchased under the Affordable Care Act, and possible drug price proposals in President Donald Trump鈥檚 upcoming budget. Plus, Rovner interviews Andy Slavitt, who this week launched a health care advocacy group called 鈥淭he United States of Care.鈥
-
As States Target High Drug Prices, Pharma Targets State Lawmakers
In Louisiana, the wining and dining of lawmakers by scores of pharma lobbyists proves a valuable lesson on how to win statehouse votes and influence profits.
By Jay Hancock and Shefali Luthra -
Podcast: KHN’s 鈥榃hat The Health?鈥 The State Of The (Health) Union
In this episode of KHN鈥檚 鈥淲hat the Health?鈥 Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo and Julie Appleby and Sarah Jane Tribble of Kaiser Health News discuss President Donald Trump鈥檚 promises to reduce drug prices in his first State of the Union Address. The panelists also discuss the departure of the director of the Centers for Disease Control and Prevention after conflict-of-interest reports and the efforts by some states to flout the Affordable Care Act.
-
Expert Advice For The Corporate Titans Taking On Health Care
Amazon, Berkshire Hathaway and JPMorgan Chase & Co. are partnering up to address employee health care costs and improve satisfaction. Can they deliver? And would repackaging health insurance involve drones?
-
Big Pharma Greets Hundreds Of Ex-Federal Workers At The 鈥楻evolving Door鈥
A KHN data analysis finds that the door of opportunities connecting Capitol Hill, the federal government and the drug industry likely spins in Big Pharma鈥檚 favor.
-
University Under Fire For Off-The-Grid Herpes Vaccine Experiments
Southern Illinois University鈥檚 medical school has halted all herpes research, one of its most high-profile projects, amid growing controversy over a researcher鈥檚 unauthorized methods offshore and in the U.S.
-
Hospital Honchos Hone New Message In Wake Of Opioid Epidemic: Expect Pain
"We really do have a lot of responsibility and culpability," says one hospital official who is part of a working group trying to address the opioid epidemic. Patients have to expect more pain after surgery and understand the risk of addiction, says another doctor.
-
J.P. Morgan Health Conference All About The Deals Amid Uncertainty For Millions
The lofty ideas floated and billion-dollar deals sealed at J.P. Morgan鈥檚 elite annual conference stand in stark contrast to the uncertainty that clouds health care outside its confines.
-
Fallout From ‘Nuclear Button鈥 Tweets: Sales Of Anti-Radiation Drug Skyrocket
Orders for potassium iodide reportedly jumped after a Jan. 2 war of words between Trump and North Korea鈥檚 Kim Jong-un.
-
Facebook Live: It鈥檚 2018, Can Big Pharma Hold The Line Against Pricing Controls?
In this chat, KHN senior correspondent Jay Hancock discusses how drug-pricing battles could play out this year in D.C., state legislatures and beyond. What do we know about the drug industry鈥檚 agenda to quiet the drumbeat of cost control and transparency proposals? How will they officials target their efforts? Will the battles take place at the state level? Senior editor Stephanie Stapleton moderates.
-
HHS Nominee Vows To Tackle High Drug Costs, Despite His Ties To Industry
Alex M. Azar II, the former president of the U.S. division of Eli Lilly, says the U.S. drug system encourages price increases 鈥 but he intends to work on that problem.
-
Drug Overdose Deaths Soar Nationally But Plateau In Some Western States
Fatalities are climbing in states that have been flooded by the deadly opioid fentanyl, but are remaining flat 鈥 or even falling 鈥 in many Western states, where the drug has not yet been as common as other parts of the country.
-
Grassley Calls For 鈥楥orrective Action鈥 On Abuses In Herpes Vaccine Research
The Republican senator sent out letters to the Food and Drug Administration and HHS demanding an explanation about a rogue herpes vaccine trial.
-
From Retirement To The Front Lines Of Hepatitis C Treatment
This doctor came out of retirement with the goal of treating every patient at high risk for hepatitis C he encounters. The problem is finding them.
-
Readers Have Bones To Pick, From Health System Flaws To Covering Pot Beat
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
-
FDA Chief Says He鈥檚 Open To Rethinking Incentives On Orphan Drugs
The FDA鈥檚 Scott Gottlieb says the agency is focused on the big picture, and he wants to know why pharma churns out drugs for some rare diseases but not for others.
-
Arthritis Drugs Show How U.S. Drug Prices Defy Economics
Drugs that treat rheumatoid arthritis started out costing about $10,000 a year. Ten years later, they list for more than $40,000.
-
Biosimilars, Biologics And New Legal Challenges For RA Treatments
As biosimilar products reach the market and rival more established RA treatments, the players are exploring legal challenges involving antitrust and anti-competitive behavior.